FOLH1 and prostate cancer: We found evidence of PSL in 0.13% of all male patients who had PET/CT scans performed for evaluation of known or suspected oncological diseases, and in 0.61% of those with suspected or confirmed prostate cancer who had undergone Ga 68-PSMA studies.